HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:
Sign In to gain access to subscriptions and/or personal tools.

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Request Reprints Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (24) Citing Articles via Google Scholar Google Scholar Articles by Faessel, H. M. Articles by Burstein, A. H. Search for Related Content PubMed PubMed Citation Articles by Faessel, H. M. Articles by Burstein, A. H. Social Bookmarking                         What's this?

Single-Dose Pharmacokinetics of Varenicline, a Selective Nicotinic Receptor Partial Agonist, in Healthy Smokers and Nonsmokers

From the Departments of Clinical Pharmacokinetics and Pharmacodynamics (Dr Faessel, Dr Gibbs), Pharmacokinetics, Pharmacodynamics, and Metabolism (Dr Smith, Mr Gobey), and Medical and Developmental Sciences (Dr Faessel, Dr Gibbs, Dr Clark, Dr Burstein), Pfizer Global Research and Development, Groton, Connecticut.

Varenicline is a novel and selective 4ß2 nicotinic receptor partial agonist that is under development for smoking cessation. The primary objectives of this double-blind, placebo-controlled, single-dose, dose-escalation study were to determine the clinical pharmacology of single doses of varenicline in healthy smokers and nonsmokers under fed and fasted conditions and to determine the clinical pharmacology of varenicline administered in the morning and in the evening to smokers. Within each subject group, 4 subjects were randomized to varenicline and 2 subjects to placebo. Subjects received one single oral administration of varenicline or placebo: 6 doses (0.01, 0.03, 0.1, 0.3, 1.0, and 3.0 mg) were investigated in nonsmokers and 7 doses in smokers (0.01, 0.03, 0.1, 0.3, 1.0, 3.0, and 10.0 mg). Varenicline was well tolerated after single doses up to 3.0 mg in smokers and 1.0 mg in nonsmokers. Nausea and vomiting at doses above 3.0 mg in smokers and 1.0 mg in nonsmokers were dose limiting. Systemic exposure to varenicline and pharmacokinetic variability were similar between smokers and nonsmokers. Coadministration with food, smoking restriction, and time-of-day dosing did not affect the pharmacokinetics of varenicline.

Key Words: Varenicline • single-dose pharmacokinetics • food effect • evening dosing

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				A. A Kreshak, A. K Clark, R. F Clark, B. T Ly, and F L. Cantrell A Retrospective Poison Center Review of Varenicline-Exposed Patients Ann. Pharmacother., December 1, 2009; 43(12): 1986 - 1991. [Abstract] [Full Text] [PDF]

				K. O. Fagerstrom and C. A. Jimenez-Ruiz Pharmacological treatments for tobacco dependence Eur. Respir. Rev., December 1, 2008; 17(110): 192 - 198. [Abstract] [Full Text] [PDF]

				A. H. Burstein, D. J. Clark, M. O'Gorman, S. A. Willavize, T. G. Brayman, G. S. Grover, R. L. Walsky, R. S. Obach, and H. M. Faessel Lack of Pharmacokinetic and Pharmacodynamic Interactions Between a Smoking Cessation Therapy, Varenicline, and Warfarin: An In Vivo and In Vitro Study J. Clin. Pharmacol., November 1, 2007; 47(11): 1421 - 1429. [Abstract] [Full Text] [PDF]

				A. H. Burstein, T. Fullerton, D. J. Clark, and H. M. Faessel Pharmacokinetics, safety, and tolerability after single and multiple oral doses of varenicline in elderly smokers. J. Clin. Pharmacol., November 1, 2006; 46(11): 1234 - 1240. [Abstract] [Full Text] [PDF]